Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 4, 2001, Pages 392-396

  Recchia, Francesco ^a,b,d   De Filippis, Sandro ^a   Rosselli, Michele ^b   Saggio, Gaetano ^a   Pompili, Pierluigi ^b   Piccinini, Massimo ^b   Rea, Silvio ^b,c  

^a Ospedale Civile   (Italy)

^b CROFI Fondazione Ferri Monterotondo   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d NONE   (Italy)

Author keywords

5 Fluorouracil infusion; Cyclophosphamide; Epirubicin; Metastatic breast cancer

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; SEROTONIN ANTAGONIST; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG INDUCED DISEASE; DRUG INFUSION; FEMALE; HUMAN; METASTASIS; NEUTROPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034906762     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200108000-00018     Document Type: Article

References (25)

1. Treatment of breast cancer
2. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer
3. Dose-response is alive and well
4. Dose-response in the treatment of breast cancer: A critical review
5. Dose-response effect of adjuvant chemotherapy in breast cancer
6. Pharmacokinetics of 5-fluorouracil in humans
7. Fluorinated pyrimidines: A new class of tumor inhibitory compounds
8. Time-dose relationship for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro
9. Continuous infusion fluorouracil in the management of advanced breast cancer: A phase II study
10. Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4′-epi-doxorubicin in guinea pig heart muscle
11. Italian multicentre breast study with epirubicin Phase II randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre study
12. French epirubicin study group A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin
13. Phase II study of doxorubicin versus epirubicin in advanced breast cancer
14. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
15. Alkylating agents
16. Nonparametric estimation from incomplete observations
17. Reporting results of cancer treatment
18. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast
19. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: An active new regimen
20. High complete remission rate with primary neoadjuvant infusional chemotherapy for large early breast cancer
21. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte-colony stimulating factor in advanced breast cancer
22. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial
23. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
24. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study
25. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over